Document Detail

Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial.
MedLine Citation:
PMID:  11245648     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: beta-Blockade-induced benefit in heart failure (HF) could be related to baseline heart rate and treatment-induced heart rate reduction, but no such relationships have been demonstrated. METHODS AND RESULTS: In CIBIS II, we studied the relationships between baseline heart rate (BHR), heart rate changes at 2 months (HRC), nature of cardiac rhythm (sinus rhythm or atrial fibrillation), and outcomes (mortality and hospitalization for HF). Multivariate analysis of CIBIS II showed that in addition to beta-blocker treatment, BHR and HRC were both significantly related to survival and hospitalization for worsening HF, the lowest BHR and the greatest HRC being associated with best survival and reduction of hospital admissions. No interaction between the 3 variables was observed, meaning that on one hand, HRC-related improvement in survival was similar at all levels of BHR, and on the other hand, bisoprolol-induced benefit over placebo for survival was observed to a similar extent at any level of both BHR and HRC. Bisoprolol reduced mortality in patients with sinus rhythm (relative risk 0.58, P:<0.001) but not in patients with atrial fibrillation (relative risk 1.16, P:=NS). A similar result was observed for cardiovascular mortality and hospitalization for HF worsening. CONCLUSIONS: BHR and HRC are significantly related to prognosis in heart failure. beta-Blockade with bisoprolol further improves survival at any level of BHR and HRC and to a similar extent. The benefit of bisoprolol is questionable, however, in patients with atrial fibrillation.
P Lechat; J S Hulot; S Escolano; A Mallet; A Leizorovicz; M Werhlen-Grandjean; G Pochmalicki; H Dargie
Related Documents :
2295248 - Severe bradycardia following electrical cardioversion for atrial tachyarrhythmias in pa...
2595728 - Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the ...
4031728 - Evaluation of transthoracic countershock with initial energy levels up to 200 j in a co...
22240768 - Percutaneous coronary intervention with or without on-site coronary artery bypass surge...
7967008 - Time course of the recovery of adenosine triphosphate content with adenosine in post-is...
3494368 - Reproducibility and reliability of first pass radionuclide ventriculography with au-195...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Circulation     Volume:  103     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-14     Completed Date:  2001-05-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1428-33     Citation Subset:  IM    
Pharmacology Department, Pitié Salpêtrière Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology,  therapeutic use
Aged, 80 and over
Bisoprolol / pharmacology,  therapeutic use*
Blood Pressure / drug effects
Chronic Disease
Heart Diseases / drug therapy*,  mortality,  physiopathology
Heart Rate / drug effects*
Middle Aged
Multivariate Analysis
Survival Rate
Time Factors
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 66722-44-9/Bisoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Qtc interval as a guide to select those patients with congestive heart failure and reduced left vent...
Next Document:  Catheter ablation of typical atrial flutter: a randomized comparison of 2 methods for determining co...